A newer immunoglobulin intravenous (IGIV) - Gammagard® liquid 10%: Evaluation of efficacy, safety, tolerability and impact on patient care

Expert Opinion on Biological Therapy

Volumn 8, Issue 6, 2008, Pages 799-804

  Shah, Sachin R ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Autoimmune disorder; Efficacy; IGIV; Immunodeficiency; Immunoglobulin; IVIG; Liquid; Safety

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; KIOVIG;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ASEPTIC MENINGITIS; CHILL; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MANUFACTURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HEADACHE; HEMOLYSIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; LIQUID; MIGRAINE; NAUSEA; NEPHROSIS; PATIENT CARE; POWDER; RECOMMENDED DRUG DOSE; REVIEW; RIGOR; VOMITING;

ADOLESCENT; ADULT; AGED; CHEMICAL FRACTIONATION; CHILD; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION ROUTES; DRUG CONTAMINATION; FEMALE; GLYCINE; HEADACHE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLASMA; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SOLUTIONS;

EID: 45549093691     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.6.799     Document Type: Review

References (36)

1. Von Behring E, Kitasato S. Uber das Zustandekommen der diphterieimmunitaet und der tetanus-immunitant bei thieren. Dtsch Med Wochenschr 1890;16:1113-4
2. Good RA, Lorenz E. Historic aspects of intravenous immunoglobulin therapy. Cancer 1991;68:1415-21 • An excellent review of immunoglobulin history. This paper discusses earlier production, administration and side-effects challenges of immunoglobulin.
3. Ratko TA, Burnett DA, Foulke GE, et al. Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA 1995;273:1865-70
4. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006;46:741-53
5. Weeks JS, Tierney MR, Weinstein MC. Cost-effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991;325:81-6
6. Cordonnier C, Chevret S, Legarand M, et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 2003;139:8-18
7. Spector SA, Gelber RD, McGrath N, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immuneodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med 1994;331:1181-7
8. Intravenous Immuno Globulin. Available from: http://www.blooddiagnostics. com/Comparison%20Charts/IVIG_Chart.pdf [Last accessed 2/6/08]
9. IvIg therapies. Available from: http://www.medprorx.com/forms/ MedProRx_IVIg_chart.pdf [Last accessed 2/6/08]
10. Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006;6:592-9
11. Baxter Healthcare Corporation. Gammagard liquid (Immune Globulin Intravenous (Human) 10%) package insert. Westlake Village, CA; April 2005
12. Bjorkander J, Nikoskelainen J, Leibl H, et al. Prospective open-label study of pharmacokinetics, efficacy and safety of new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang 2006;90:286-93
13. Poelsler G, Berting A, Kindermann J, et al. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps. Virus and prion reduction capacity. Vox Sang 2008:94(3):184-92
14. Church JA, Leibl H, Stein MR, et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin (IGIV 10%) in patients with primary immunodeficiency. J Clin Immunol 2006;26:388-95
15. Ballow M, Berger M, Bonilla FA, et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang 2003;84:202-10
16. Berger M, Pinciaro PJ; Flebogamma® 5% Investigators. Safety, efficacy, and pharmacokinetics of Flebogamma(R) 5% (immune globulin intravenous (human)) for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 2004;24:389-96
17. Varga G, Volkova Z, Leibl H, et al. Efficacy and safety of the new intravenous immunoglobulin IGIV 10% in adults with chronic idiopathic thrombocytopenic purpura. Transfus Med Hemother 2006;33:509-14
18. Renal insufficiency and failure associated with immune globulin intravenous therapy - United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999;48:518-21
19. Sati HI, Ahya R, Watson HG. Incidence and associations of acuter renal failure complicating high-dose intravenous immunoglobulin therapy. Br J Haematol 2001;113:556-7
20. Shah S, Vervan M. Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis. Am J Health Syst Pharm 2005;62:720-5
21. Ochs HD, Pinciaro PJ; The Octagam Study Group. Octagam® 5%, an intravenous IgG product, is efficacious and well tolerate in subjects with primary immunodeficiency diseases. J Clin Immunol 2004;24:309-14
22. Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006;26:265-73
23. CSL Behring LLC. Privigen™ (Immune Globulin Intravenous (Human) 10% liquid) package insert. Kankakee, IL 60901; July 2007
24. Berger M, Cunningham-Rundles C, Bonilla FA, et al. Carimune NF liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immujodeficiency diseases. J Clin Immunol 2007;27:503-9
25. Roifman CM, Schroeder H, Berger M, et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency - a randomized double-blind trial. Int Immunopharmacol 2003;3:1325-33
26. Wolf HH, Davies SV, Borte M, et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 2003;84:45-53
27. Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 2002;359:23-9
28. Yap PL. The viral safety of intravenous immune globulin. Clin Exp Immunol 1996;104(Suppl 1):35-42
29. Bresee JS, Mast EE, Coleman PJ, et al. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. JAMA 1996;276:1563-7
30. Healey CJ, Sabharwal NK, Daub J, et al. Outbreak of acute hepatitis C following the use of anti-hepatitis C virus-screened intravenous immunoglobulin therapy. Gastroenterology 1996;100:1120-6
31. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1994;43:505-9
32. Berger A, Doerr HW, Scharrer I, Weber B. Follow-up of four HIV-infected individuals after administration of hepatitis C virus and GBV-C/hepatitis G virus contaminated intravenous immunoglobulin: evidence for HCV but not for GBV-C/HGV transmission. J Med Virol 1997;53:25-30
33. Yap LP. Intravenous immunoglobulin and hepatitis C virus: an overview of transmission episodes with emphasis on manufacturing data. Clin Ther 1996;18(Suppl B):43-58
34. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003;17:241-51 • An excellent review of the risks associated with administration of intravenous immunogolobulin.
35. McCue JP, Hein RH, Tenold R. Three generation of immunoglobulin G prepartions for clinical use. Rev Infect Dis 1986;8(Suppl 4):S374-81
36. Talecris Biotherapeutics, Inc. Gamunex® (Immune Globulin Intravenous (Human), 10% caprylate/chromatography purified) package insert. Research triangle park, NC; November 2005